293 related articles for article (PubMed ID: 24096380)
1. At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies.
Locatelli F; Merli P; Rutella S
J Leukoc Biol; 2013 Dec; 94(6):1141-57. PubMed ID: 24096380
[TBL] [Abstract][Full Text] [Related]
2. Natural killer cells in the treatment of high-risk acute leukaemia.
Locatelli F; Moretta F; Brescia L; Merli P
Semin Immunol; 2014 Apr; 26(2):173-9. PubMed ID: 24613727
[TBL] [Abstract][Full Text] [Related]
3. At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias.
Norell H; Moretta A; Silva-Santos B; Moretta L
J Leukoc Biol; 2013 Dec; 94(6):1123-39. PubMed ID: 24108703
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. Negative depletion of α/β+ T cells and of CD19+ B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation.
Locatelli F; Bauquet A; Palumbo G; Moretta F; Bertaina A
Immunol Lett; 2013; 155(1-2):21-3. PubMed ID: 24091162
[TBL] [Abstract][Full Text] [Related]
6. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
7. The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond.
Tsirigotis P; Shimoni A; Nagler A
Ann Med; 2014 Sep; 46(6):384-96. PubMed ID: 24888385
[TBL] [Abstract][Full Text] [Related]
8. Strategies to optimize the outcome of children given T-cell depleted HLA-haploidentical hematopoietic stem cell transplantation.
Locatelli F; Vinti L; Palumbo G; Rossi F; Bertaina A; Mastronuzzi A; Bernardo ME; Rutella S; Dellabona P; Giorgiani G; Moretta A; Moretta L
Best Pract Res Clin Haematol; 2011 Sep; 24(3):339-49. PubMed ID: 21925087
[TBL] [Abstract][Full Text] [Related]
9. Innate Immune Responses in the Outcome of Haploidentical Hematopoietic Stem Cell Transplantation to Cure Hematologic Malignancies.
Zaghi E; Calvi M; Di Vito C; Mavilio D
Front Immunol; 2019; 10():2794. PubMed ID: 31849972
[TBL] [Abstract][Full Text] [Related]
10. Cell therapy: achievements and perspectives.
Bordignon C; Carlo-Stella C; Colombo MP; De Vincentiis A; Lanata L; Lemoli RM; Locatelli F; Olivieri A; Rondelli D; Zanon P; Tura S
Haematologica; 1999 Dec; 84(12):1110-49. PubMed ID: 10586214
[TBL] [Abstract][Full Text] [Related]
11. Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study.
Barkholt L; Alici E; Conrad R; Sutlu T; Gilljam M; Stellan B; Christensson B; Guven H; Björkström NK; Söderdahl G; Cederlund K; Kimby E; Aschan J; Ringdén O; Ljunggren HG; Dilber MS
Immunotherapy; 2009 Sep; 1(5):753-64. PubMed ID: 20636021
[TBL] [Abstract][Full Text] [Related]
12. Role of alloreactive KIR2DS1(+) NK cells in haploidentical hematopoietic stem cell transplantation.
Marcenaro E; Carlomagno S; Pesce S; Della Chiesa M; Moretta A; Sivori S
J Leukoc Biol; 2011 Oct; 90(4):661-7. PubMed ID: 21791599
[TBL] [Abstract][Full Text] [Related]
13. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation.
Passweg JR; Tichelli A; Meyer-Monard S; Heim D; Stern M; Kühne T; Favre G; Gratwohl A
Leukemia; 2004 Nov; 18(11):1835-8. PubMed ID: 15457184
[TBL] [Abstract][Full Text] [Related]
14. Innate immunity against hematological malignancies.
Ruggeri L; Capanni M; Tosti A; Urbani E; Posati S; Aversa F; Martelli MF; Velardi A
Cytotherapy; 2002; 4(4):343-6. PubMed ID: 12396834
[TBL] [Abstract][Full Text] [Related]
15. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.
Ruggeri L; Capanni M; Urbani E; Perruccio K; Shlomchik WD; Tosti A; Posati S; Rogaia D; Frassoni F; Aversa F; Martelli MF; Velardi A
Science; 2002 Mar; 295(5562):2097-100. PubMed ID: 11896281
[TBL] [Abstract][Full Text] [Related]
17. Natural killer cell-based immunotherapy with CTLA4Ig-primed donor lymphocytes following haploidentical transplantation.
Jaiswal SR; Chakrabarti S
Immunotherapy; 2019 Oct; 11(14):1221-1230. PubMed ID: 31478424
[TBL] [Abstract][Full Text] [Related]
18. The role of gamma delta T cells in haematopoietic stem cell transplantation.
Minculescu L; Sengeløv H
Scand J Immunol; 2015 Jun; 81(6):459-68. PubMed ID: 25753378
[TBL] [Abstract][Full Text] [Related]
19. A promising sword of tomorrow: Human γδ T cell strategies reconcile allo-HSCT complications.
Hu Y; Cui Q; Luo C; Luo Y; Shi J; Huang H
Blood Rev; 2016 May; 30(3):179-88. PubMed ID: 26654098
[TBL] [Abstract][Full Text] [Related]
20. Use of natural killer cells in hematopoetic stem cell transplantation.
Passweg JR; Stern M; Koehl U; Uharek L; Tichelli A
Bone Marrow Transplant; 2005 Apr; 35(7):637-43. PubMed ID: 15654351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
